The U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have issued a fourth temporary extension[1] (the “Fourth Temporary Extension”) of rules that allow providers to prescribe controlled substances via telemedicine without an initial in-person exam through December 31, 2026. These rules, first introduced during the COVID-19 public health emergency,…
We are pleased to announce today that Chambers USA ranked Milligan Lawless, P.C. and 4 of our attorneys among the best in Arizona for 2025. Among Arizona law firms, Milligan Lawless achieved a Band 1 ranking, Chambers USA’s highest recognition, in the Healthcare practice area. Chambers USA is an annual ranking that assesses each law…
For the first time in over a decade, the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) has proposed an update to modify the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Security Rule (the “Security Rule”). OCR stated that its goal of the proposed rule[1] (the “Proposed Rule”), is…
The Best Lawyers in America© is the longest-running peer-review publication in the legal profession.
We are pleased to announce today that Chambers USA ranked Milligan Lawless, P.C. and 4 of our attorneys among the best in Arizona for 2024. Among Arizona law firms, Milligan Lawless achieved a Band 1 ranking, Chambers USA’s highest recognition, in the Healthcare practice area. Chambers USA is an annual ranking that assesses each law…
The Eliminating Kickbacks in Recovery Act (“EKRA”) was enacted in 2018 in an effort to address fraud occurring in substance use disorder (“SUD”) treatment. EKRA prohibits paying, receiving, or soliciting remuneration in return for patient referrals to laboratories, recovery homes, and clinical treatment facilities.[1] Under EKRA, clinical treatment facilities are defined broadly to include, “a…
The materials provided in this website are for informational purposes only and are not for the purpose of providing legal advice. Transmission of information from the ML website is not intended to create, and its receipt by you does not create an attorney-client relationship with ML or any of its individual attorneys or personnel.
If you elect to communicate with anyone at ML through this website, or otherwise, in connection with a matter for which we do not already represent you, your communication can not be treated as privileged or confidential. Do not transmit any information about any matter (and particularly not information you regard as confidential) that may involve you until ML has agreed to represent you, and you have received confirmation of that fact in the form of a written engagement letter.